Vineeta MEENA, Azka GULL, Neha JAIN, Swati MADAN, Dhruv KUMAR, Rajani MATHUR, Satyendra KUMAR RAJPUT

Development and Assessment of Mitoxantrone and 4- Methyl Umbelliferone Nanoemulsions for Chemotherapeutic Potential on MCF-7 Cell Line

Every year, millions of new cases of cancer of various forms are identified, resulting in a high mortality rate. For the management of breast cancers, chemotherapeutics such as Mitoxantrone (MTO) and 4-Methyl Umbelliferone(4-MU), show significant cytotoxic effects. The goal of this research was to develop and characterize nanoemulsion of MTO and 4-MU and to further assess the cytotoxic activity of this formulation against MCF-7 cell lines using MTT assay. Aqueous microtitration technique was employed to prepare the nanoemulsion using cinnamaldehyde as an oil phase, Tween-80 as a surfactant, and PEG-400 as a co-surfactant. The developed nanoemulsions were characterized for droplet size, PDI, %transmittance, drug content, surface morphology, and in vitro release. Photomicrograph of developed NE showed spherical droplets with a mean diameter of 113.2±5.3 nm and 123.2±6.17 nm for 4-MU and MTO, respectively, and a PDI was found to be 0.254 and 0.281 for 4-MU and MTO respectively. Approximately 78.53±4.61 % of 4-MU were released under sink conditions after 8 hours in a dissolution study. MTO-NE and 4-MU-NE had a longer drug release profile in the in-vitro method when compared to standard drug solutions. The cytotoxic effect of 4-MU and 4-MU-NE was assessed on the MCF-7 cell line by MTT assay and exhibited IC50s of 3.868 mM and 1.885 Mm against MCF-7, respectively. MTO and MTO-NE had IC50s of 10.51μM and 5.027 μM against MCF-7, respectively. The results of this study show the great potential of the prepared nanoemulsions for breast cancer; hence it can be concluded that developed NEs of chemotherapeutics lead the way forward for further in-vivo research.

PDF

___

[1] Hayes A, Huang W, Yu J, Maisonpierre P, Liu A, Kern F, et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer. 2000;83(9):1154-60. [CrossRef]
[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. [CrossRef]
[3] Verma D, Khuroo T, Talegaonkar S, Iqbal Z. Nanopotentiated combination cancer therapy: Chemotherapeutic and chemosensitizer (2C approach). Med Hypotheses. 2015;84(6):580-2. [CrossRef]
[4] Fang X, Cao J, Shen A. Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy. J Drug Deliv Sci Technol. 2020;57:101662. [CrossRef]
[5] Bugde P, Biswas R, Merien F, Lu J, Liu D-X, Chen M, et al. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opin Ther Targets. 2017;21(5):511-30. [CrossRef]
[6] Barar J, Kafil V, Majd MH, Barzegari A, Khani S, Johari-Ahar M, et al. Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. J Nanobiotechnology. 2015;13(1):1-16. [CrossRef]
[7] Liu J, Ye Z, Xiang M, Chang B, Cui J, Ji T, et al. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance. Biomaterials. 2019;223:119475. [CrossRef]
[8] Yahya RS, El-Bindary AA, El-Mezayen HA, Abdelmasseh HM, Eissa MA. Biochemical evaluation of hyaluronic acid in breast cancer. Clin Lab. 2014;60(7):1115-21. [CrossRef]
[9] Karalis TT, Heldin P, Vynios DH, Neill T, Buraschi S, Iozzo RV, et al. Tumor-suppressive functions of 4-MU on breast cancer cells of different ER status: Regulation of hyaluronan/HAS2/CD44 and specific matrix effectors. Matrix Biol. 2019;78:118-38. [CrossRef]
[10] Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, et al. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010;70(7):2613-23. [CrossRef]
[11] Neubi GMN, Opoku-Damoah Y, Gu X, Han Y, Zhou J, Ding Y. Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy. Biomater Sci. 2018;6(5):958-73. [CrossRef]
[12] Iqbal R, Ahmed S, Jain GK, Vohora D. Design and development of letrozole nanoemulsion: A comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. Int J Pharm. 2019;565:20-32. [CrossRef]
[13] Azeem A, Rizwan M, Ahmad FJ, Iqbal Z, Khar RK, Aqil M, et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech. 2009;10(1):69-76. [CrossRef]
[14] Liu Y, An T, Wan D, Yu B, Fan Y, Pei X. Targets and mechanism used by cinnamaldehyde, the main active ingredient in cinnamon, in the treatment of breast cancer. Front Pharmacol. 2020;11:1751. [CrossRef]
[15] Ghosh V, Mukherjee A, Chandrasekaran N. Ultrasonic emulsification of food-grade nanoemulsion formulation and evaluation of its bactericidal activity. Ultrason Sonochem. 2013;20(1):338-44. [CrossRef]
[16] Georgiev MT, Aleksova LA, Kralchevsky PA, Danov KD. Phase separation of saturated micellar network and its potential applications for nanoemulsification. Colloids Surf Physicochem Eng Aspects. 2020;607:125487. [CrossRef]
[17] Alkhatib MH, AlBishi HM. In vitro evaluation of antitumor activity of doxorubicin-loaded nanoemulsion in MCF-7 human breast cancer cells. J Nanopart Res. 2013;15(3):1-15. [CrossRef]
[18] Gull A, Ahmed S, Ahmad FJ, Nagaich U, Chandra A. Effect of polyherbal microemulsion on Staphylococcus epidermidis: Formulation development, CCD based optimization, characterization, and antibacterial activity by scanning electron microscopy. J Drug Deliv Sci Technol. 2020;57:101641. [CrossRef]
[19] Iqbal R, Ahmed S, Jain GK, Vohora D. Design and development of letrozole nanoemulsion: A comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. Int J Pharm. 2019;565:20-32. [CrossRef]
[20] Ahmed S, Gull A, Alam M, Aqil M, Sultana Y. Ultrasonically tailored, chemically engineered and “QbD” enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex-vivo permeation and stability study. Ultrason Sonochem. 2018;41:213-26. [CrossRef]
[21] Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization. Drug Deliv Transl Res. 2016;6(3):289-98. [CrossRef]
[22] Kumar S, Ali J, Baboota S. Design Expert® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. Nanotechnology. 2016;27(43):435101. [CrossRef]
[23] Gulati N, Nagaich U, Saraf SA. Intranasal delivery of chitosan nanoparticles for migraine therapy. Sci Pharm. 2013;81(3):843-54. [CrossRef]
[24] Kawish S, Ahmed S, Gull A, Aslam M, Pandit J, Aqil M, et al. Development of nabumetone loaded lipid nano-scaffold for the effective oral delivery; optimization, characterization, drug release and pharmacodynamic study. J Mol Liq. 2017;231:514-22. [CrossRef]
[25] Ahmed S, Gull A, Aqil M, Ansari MD, Sultana Y. Poloxamer-407 thickened lipid colloidal system of agomelatine for brain targeting: Characterization, brain pharmacokinetic study and behavioral study on Wistar rats. Colloids Surf B Biointerfaces. 2019;181:426-36. [CrossRef]
[26] Khuroo T, Verma D, Khuroo A, Ali A, Iqbal Z. Simultaneous delivery of paclitaxel and erlotinib from dual drug loaded PLGA nanoparticles: Formulation development, thorough optimization and in vitro release. J Mol Liq. 2018;257:52-68. [CrossRef]
[27] Verma D, Thakur PS, Padhi S, Khuroo T, Talegaonkar S, Iqbal Z. Design expert assisted nanoformulation design for co-delivery of topotecan and thymoquinone: Optimization, in vitro characterization and stability assessment. J Mol Liq. 2017;242:382-94. [CrossRef]
[28] Anzar N, Mirza MA, Anwer K, Khuroo T, Alshetaili AS, Alshahrani SM, et al. Preparation, evaluation and pharmacokinetic studies of spray dried PLGA polymeric submicron particles of simvastatin for the effective treatment of breast cancer. J Mol Liq. 2018;249:609-16. [CrossRef]
[29] Khuroo T, Verma D, Talegaonkar S, Padhi S, Panda AK, Iqbal Z. Topotecan–tamoxifen duple PLGA polymeric nanoparticles: investigation of in vitro, in vivo and cellular uptake potential. Int J Pharm. 2014;473(1-2):384-94. [CrossRef]
[30] Padhi S, Mirza MA, Verma D, Khuroo T, Panda AK, Talegaonkar S, et al. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: An appraisal of its in vitro Behavior and tumor amelioration potential. Drug Deliv. 2016;23(8):2827-37. [CrossRef]
[31] A Ansari K, J Torne S, Vavia PR, Trotta F, Cavalli R. Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr Drug Del. 2011;8(2):194-202. [CrossRef]